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Plasma concentrations of biologically active vitamin D (1,25-
(OH)2D) are tightly controlled via feedback regulation of renal
1-hydroxylase (CYP27B1; positive) and 24-hydroxylase
(CYP24A1; catabolic) enzymes. In pregnancy, this regulation is
uncoupled, and 1,25-(OH)2D levels are significantly elevated,
suggesting a role in pregnancy progression. Epigenetic regula-
tion ofCYP27B1 andCYP24A1 has previously been described in
cell and animal models, and despite emerging evidence for a
critical role of epigenetics in placentation generally, little is
known about the regulation of enzymes modulating vitamin D
homeostasis at the fetomaternal interface. In this study, we
investigated the methylation status of genes regulating vitamin
D bioavailability and activity in the placenta. Nomethylation of
the VDR (vitamin D receptor) and CYP27B1 genes was found in
any placental tissues. In contrast, the CYP24A1 gene is methyl-
ated in human placenta, purified cytotrophoblasts, and primary
and cultured chorionic villus sampling tissue. No methylation
was detected in any somatic human tissue tested. Methylation
was also evident in marmoset and mouse placental tissue. All
three genes were hypermethylated in choriocarcinoma cell
lines, highlighting the role of vitaminDderegulation in this can-
cer. Gene expression analysis confirmed a reduced capacity for
CYP24A1 inductionwith promotermethylation in primary cells
and in vitro reporter analysis demonstrated that promoter
methylation directly down-regulates basal promoter activity
and abolishes vitamin D-mediated feedback activation. This
study strongly suggests that epigenetic decoupling of vitamin D
feedback catabolism plays an important role in maximizing
active vitamin D bioavailability at the fetomaternal interface.
In eutherian mammals, proper fetal growth and develop-
ment are dependent on the formation and function of the pla-
centa. In combination with the maternal decidua, cells of the
placenta (primarily trophoblasts) regulate the exchange of
nutrients, growth factors, oxygen, and waste between maternal
and fetal circulations. The placenta also protects the developing
pregnancy from the maternal immune system (1).
Althoughmammalian placentas share a basic common func-
tion in modulating exchange at the fetomaternal interface, it is
clear that the human placenta is unique in structure and func-
tion (2). Animal models may therefore be of limited value in
fully dissecting processes underlying certain aspects of human
pathologies, such as pre-eclampsia and gestational trophoblas-
tic disease (3). An examination of human placentation is there-
fore critical in understanding its unique function and potential
role in disease.
The biologically active form of vitaminD (1,25-(OH)2D)4 is a
potent secosteroid hormone. Its wide ranging actions include
regulating calcium and phosphorus homeostasis, immune sys-
tem modulation, cellular differentiation, and apoptosis (4–6).
It also has potent antiproliferative effects (7–9). VitaminDdefi-
ciency has been linked to several adverse pregnancy outcomes,
including those associated with placental insufficiency (includ-
ing pre-eclampsia) (10, 11).
Although concentrations of 1,25-(OH)2D are low in the early
embryo, circulating maternal levels are elevated (2-fold) dur-
ing pregnancy (reviewed in Ref. 12), and it is clear that a large
proportion of maternal circulating 1,25-(OH)2D is derived
from decidua and placental cells (13). There is inconsistent evi-
dence regarding transplacental transfer of 1,25-(OH)2D from
mother to fetus (14, 15), but it is clear that the immediate pre-
cursor, 25-(OH)2D, crosses from maternal to fetal circulations
(16). At birth, fetal and maternal levels of 25-(OH)2D are com-
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parable, and indirect measures suggest that 1,25-(OH)2D may
also be correlated (17).
Several components of the vitamin D pathway are strongly
expressed in human uterine decidua and placental tissues from
early pregnancy (18, 19). VDR (vitamin D receptor)-bound
1,25-(OH)2D regulates key target genes associatedwith implan-
tation and trophoblast functioning (including specific cyto-
kines and homeobox genes (18–20). 1,25-(OH)2D has been
shown to directly modulate the production of human chorioric
gonadotrophin in human trophoblasts, and reduced expression
and activity of 1-hydroxylase has been reported in differentiat-
ing trophoblast cells undergoing syncitialization in vitro (18). A
supportive role of vitaminD in placental function is also evident
by its influence on human placental lactogen, estradiol, and
progesterone gene transcription (21, 22). In addition, vitamin
D, in the form of 1,25-(OH)2D can function as an intracrine
regulator of antibacterial responses in human trophoblasts that
may lead to a novel mode of activation of innate immune
responses in the placenta (23). Given its potent immunosup-
pressive effects, 1,25-(OH)2D may also play a role in implanta-
tion tolerance (19). The vitamin D metabolic pathway involves
multiple enzymatic reactions, each of which is a potential target
for epigenetic regulation. The CYP27B1 (1-hydroxylase) gene
product, 1-hydroxylase, is directly responsible for the produc-
tion of 1,25-(OH)2D from 25-(OH)2D. Largely expressed in the
kidney, it is also expressed in decidual cells and the placenta
(24). In contrast, 1,25-(OH)2D-hydroxylase (24-hydroxylase),
encoded by the CYP24A1 (vitamin D 24-hydroxylase) gene,
plays a pivotal role in the attenuation of vitamin D responsive-
ness by catalyzing synthesis of less activemetabolites fromboth
1,25-(OH)2D and 25-(OH)2D (25–28). The CYP24A1 gene is
up-regulated in several cancer cell types, where it attenuates
vitamin D-mediated growth inhibition (29). However, other
cancers appear to showdecreased activity of this gene (4). Inter-
estingly, a lack of expression of CYP24A1 has been directly
associated with DNA methylation of the upstream promoter
and first exon regions in tumor-derived endothelial cells in
mice and rat osteoblastic ROS17/2.8 cells (30, 31).
The importance of epigenetic regulation in placental devel-
opment and function is becoming increasingly apparent. Gen-
eral disruption of DNA methylation using drug treatment has
been shown to disrupt placental development and also inhibit
invasiveness in trophoblast cell models (32, 33). In addition to
the well documented parent-of-origin specific imprinting of
genes in the placenta (reviewed in Ref. 34), specific epigenetic
silencing of nonimprinted genes has also recently been
reported (35–38). This is likely to play a role in many aspects of
placental functioning.
Very little is known about the epigenetic regulation of
enzymes modulating vitamin D homeostasis at the fetomater-
nal interface. Given the likely importance of 1,25-(OH)2D in
proper placental development and functioning, fetal develop-
ment, and themodulation of maternal immune response to the
developing fetus, we investigated epigenetic regulation of vita-
min D metabolism in human placental tissue in general and in
specific cell subtypes.
EXPERIMENTAL PROCEDURES
Tissue Isolation—Tissues were collected for research pur-
poses with approval from theHumanResearch Ethics Commit-
tees at the RoyalWomen’s Hospital (03/51),MercyHospital for
Women (R07/15), and Monash Medical Centre (07084C). For
human placental tissue sampling, a core of full-thickness tissue
was isolated from two randomly chosen sites. Tissue sections
fromother species werewashed briefly in saline before process-
ing bymaceration with a scalpel blade prior to immediate DNA
isolation. CVS samples were collected and processed as previ-
ously described (37).
First trimester human cytotrophoblast cells were isolated as
per Ref. 39, and purity of preparations was determined using
antibodies to the trophoblast-specific cytokeratin-7 (1:100
dilution, clone OV-TL 12/30; DakoCytomation, Glostrup,
Denmark) using immunocytochemistry. Cells were fixed in
ethanol, rehydrated, and treated with 0.3% hydrogen peroxide
in methanol for 10 min to block endogenous peroxidase activ-
ity. Cells were then washed with Tris-buffered saline and incu-
bated with nonimmune block for 30min. Primary antibody was
applied and incubated at 48 °C for 16 h followed by biotinylated
horse anti-mouse IgG (1:200) for 30min and then streptavidin-
biotin-peroxidase complex ABC (DakoCytomation) according
to the manufacturer’s instructions. Peroxidase activity was
visualized by application of diaminobenzidine substrate (Dako-
Cytomation) for 3–5 min. Cells were counterstained with Har-
ris hematoxylin (Sigma), air-dried, and mounted. Only cell
preparations in which 95% of the cells were positive for cyto-
keratin-7 were used for subsequent experiments.
For CVS samples (8–10 weeks of gestation), contaminating
maternal blood and decidua were removed, and 5–10 mg of
cleaned villi was separated from the diagnostic sample, washed
in isotonic saline, pelleted by centrifugation, and stored at
20 °C until DNA extraction and bisulfite modification. A cell
culture from each villi sample was established by finely macer-
ating the villi and resuspending in 1.0 ml of 0.25% trypsin with
incubation of the suspension at 37 °C for 45 min. Cells were
then resuspended in 7 ml of RPMI 1640 medium (SAFC Bio-
sciences), pelleted at 560  g, and resuspended in a small vol-
ume ofAmnioMAXmedium (Invitrogen) containing 0.5g/ml
amphotericin B. The cell suspension was then inoculated onto
glass coverslips in 35-mmPetri dishes with subsequent incuba-
tion at 37 °C in 5% CO2 in humidified air. Wells were then
flooded with 2 ml of AmnioMAX medium the following day
and were grown to around 95% confluence, trypsinized, pel-
leted, and stored at 20 °C until DNA extraction and bisulfite
modification. Cultured cells were isolated following 14–18
days in culture with a maximum of three passages.
Cell Culturing and Transfection—JEG-3 cells (HTB-36 (40)),
BeWo (CCL-98 (41)), and JAR cells (HTB-144 (42)), weremain-
tained in RPMI plus 10% fetal calf serum at 37 °C in 5% CO2.
The SV40-transformed trophoblast HIPEC-65 cell line was
maintained as previously described (43). Cells were grown for a
minimal number of passages (8) andwere split (1:5–1:8) prior
to confluence and harvesting of genomic DNA or transfection
analysis.
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For transfection experiments, a total of 8  103 JAR or
HIPEC65 cells were plated 24 h prior to transfection in each
well of a 96-well plate (96F Nunclon Delta white microwell).
Transfection was carried out using Lipofectamine LTX reagent
(Invitrogen). Luciferase and Renilla activity was measured 24 h
post-transfection using the DualGLO assay system (Promega,
Madison, WI) on a FluorSTAR Optima microplate reader
(BMGLabtech, Offenburg, Germany). For vitaminD induction
experiments, cells were treated with 10 or 100 nM 1,25-(OH)2D
(Sigma) 12 h post-transfection, with luciferase activity moni-
tored after overnight incubation. Endometrial stromal cells and
decidua were isolated as previously described (44).
Genomic DNA and Methylation Analysis—Genomic DNA
isolation and bisulfite DNA sequencing was performed as pre-
viously described (37, 38). DNA samples were processed using
the Methyl EasyTM bisulfite modification kit (Human Genetic
Signatures, Sydney, Australia) kit according to themanufactur-
er’s instructions. Amplification was performed on converted
genomic DNA using primers directed to bisulfite modified
DNA: VDRbisF1, 5-AATATTTTTTGTTCTTTAAGTGTT-
AAGTA; VDRbisF2, 5-TAAATTTTAGTGTTTTTTAGTG-
TTTTAGTT; VDRBisR1, 5-CTAACCTAATCAACCCAAA-
TAAAAATA; CYP24BisF1, 5-GGAAAGGGGGTTTTAAG-
AAATAGTA; CYP24BisR1, 5-ACTTCCAACCCCAAAAAA-
CTCTAAC; CYP24BisF2, 5-TGGTTTTAGTTAGATTTTA-
GAGGTTAGTTT; CYP24BisR2, 5-TACTATTTCTTAAAA-
CCCCCTTTCC; CYP24BisF3, 5-GAGTATGTTTTGGGTG-
GTTAATGAG; CYP24BisR3, 5-TCCAAACTAAAAATATC-
TAACTCCCC; CYP27BisF1, 5-TTTTGGTTGTTTTATAT-
TTGTTTTG; CYP27BisR1, 5-AACCATAACCCAAACC-
CTCAAATA.
Marmoset amplification primers were marF1 (5-GTATTT-
TAGGGAAGGTTTGGAG) and marR1 (5-CCTCCTTCCT-
ACAACAACAAC).Mouse primersweremF1 (5-TGTTTAG-
TAGTGGTTAGTTGGTGGG) and mR1 (5-ACATCCCTA-
AACATCTACCTCTTCC). Amplification conditions were as
follows: 95 °C for 5min, 56 °C for 1min 30 s, and 72 °C for 1min
30 s  40 cycles, 72 °C for 7 min. Resulting amplicons were
cloned into TOPO TA Cloning Vector (Invitrogen) for auto-
mated fluorescent sequencing as described inRef. 45.Datawere
analyzed using BiQ Analyser software (46), and clones showing
less than 80% conversion or that were identified as clonal in
FIGURE 1. Methylation status of CYP24A1, CYP27B1, and VDR in human term placenta. Schematic representation of methylation data generated for
regulatory regions of genes coding for 24-hydroxylase (A), 1-hydroxylase (B), and the vitamin D receptor (C). i, gene structure showing the location of
methylation assays.Graybox, CpG island;black boxes, exon regions;arrow, translational start site. ii,meanmethylation levels seenat eachCpGsite for each type
of sample tested. Numbers of each type of tissue are listed in parentheses. Between 8 and 12 individual clones were sequenced for each sample. Circles, CpG
sites denoted by vertical dashes. Closed circles, methylation; open circles, lack of methylation. Missing circles indicate CpG sites for which no information was
obtained.
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origin were not included in subsequent analysis. Mean methy-
lation levels for each amplicon were determined using the for-
mula (number of methylated CpG sites/total CpG sites exam-
ined 100).
CYP24A1Gene Reporter Assays—A758-bp region of the pro-
moter/exon 1 of the humanCYP24A1 gene previously shown to
confer vitaminD responsiveness (47)was amplified using prim-
ers; Sal_CYP24_548F (5-CTCTCTGTCGACTTGGAGCT-
CCGCAGAAAGCCAAACTTCCT) and SalI_CYP24_209R
(5-CTCTCTGTCGACGTACTCGAGACAGCCTCAGAGC-
ATTGGTG) with Phusion Hi-Fidelity DNA polymerase
(Finnzymes). The SalI-digested amplicon was cloned into a
promoterless luciferase expression vector pGL3:basic (Pro-
mega, Madison, WI) to produce the plasmid pGL3:594/
209. Reverse orientation cloning was also carried out to pro-
duce pGL:209/594. Following sequence verification, DNA
was in vitro methylated using either Sss1, HpaII, or HhaI
methylases (New England Biolabs, Ipswich, MA) according to
the manufacturer’s instructions. 100 ng of pGL3:control vector
(SV40 constitutive promoter), pGL3:basic (promoterless), or
unmethylated or methylated CYP24A1 promoter constructs
were then transfected into JAR and HIPEC65 cells. Co-trans-
fection with 10 ng of pRn (HSV-TK promoter linked to the
Renilla luciferase gene) was carried out in all cases to normalize
for transfection efficiency.
Gene Induction Experiments—24 h prior to induction, CVS-
derived cells, skin, and placental-derived fibroblasts were
seeded in a 6-well plate at a density of 250,000 cells/well. Half of
the wells were then treated with 100 nM calcitriol (Sigma), and
the other half were left untreated. Cells were then incubated for
7 h prior to total RNA isolation using TRIzol (Invitrogen)
according to the manufacturer’s instructions. cDNA synthesis
was performed with the SuperScript III kit (Invitrogen), from 1
g of total RNA. Quantitative reverse transcription-PCR was
performed in a 96-well optical plate (Applied Biosystems, Fos-
ter City, CA) on a 7300 ABi thermal cycler (Applied Biosys-
tems). The master mix consisted of 15 l of Sybr GreenMaster
Mix (Sigma), 1 l of forward primer, 1 l of reverse primer (50
pM final concentration), 8l of water, 5l of cDNA template in
a total volume of 30 l. Nondiluted cDNA was used for
CYP24A1, CYP27B1, and VDR assays, and a 1:10 dilution was
used for the GAPDH (glyceraldehyde-3-phosphate dehydro-
genase) assay. Primer sequences were as follows: CYP24A1_F,
5-CCCAAAGGAACAGTGCTCATG; CYP24A1_R, 5-TCT-
CCTGAAGCCAACGTTCAG; CYP27B1_F, 5-ATGAGGAA-
CGGAGGACAGCC; CYP27B1_R, 5-GAGCGTGTTGGAC-
ACCGTGT; VDR_F, 5-TTGCGCTCCAATGAGTCCTTC;
VDR_R, 5-CTGTGTCCGGCTTTGGTCAC; GAPDH_F, 5-
TTCGACAGTCAGCCGCATCTT; GAPDH_R,
5-CCCAATACGACCAAATCCGTT.
RESULTS
TheCYP24A1 butNot theVDRorCYP27B1Gene Promoter Is
Methylated in Full Term Human Placental Tissue—As a first
step in the identification of potential epigenetic regulation of
vitamin D levels in the placenta, we designed specific methyla-
tion amplification assays for regulatory regions of the VDR,
CYP24A1, and CYP27B1 genes. In the case of the VDR and
CYP24A1 genes, assays were designed to span the transcription
start site and exon 1 within the associated CpG island, whereas
for CYP27B1, we analyzed a region of exon 1 previously shown
to be methylated in some cancers (48, 49). Initial experiments
on human term placenta revealed a complete lack of methyla-
tion at the VDR and CYP27B1 gene regulatory regions, with
clear (but variable) methylation of the CYP24A1 promoter
region (Fig. 1 and Table 1). This was not due to problems with
specific assays, since methylation of both VDR and CYP27B1
were detected in choriocarcinoma cells (see below). Three
independent assays spanning the CYP24A1-associated CpG
island were then examined with each showing evidence of
methylation in full term placenta (supplemental Fig. 1). A total
of 10 term placentas were then examined using theCYP24A1-2
assay spanning a region of differential methylation recently
identified in the placenta by whole genome methylation data
(50). These results confirmed methylation of the CYP24A1
CpG island in all full termplacental samples, with ameanmeth-
ylation level of 56.5% (Table 1).Whereas someCYP24A1 alleles
showed nearly complete methylation, others were almost com-
pletely unmethylated. This is reminiscent of monoallelic meth-
ylation, previously described for the APC tumor suppressor
gene in the placenta (37), but may equally reflect differing
methylation profiles in a mixed population of cells.
CYP24A1 Placental Methylation in Multiple First Trimester
Placental Cell Types—In order to ascertain the cell types and
timing of methylation of the CYP24A1 promoter within the
placenta, we examined the methylation status of chorionic vil-
lous tissue (pre- and post-cell culturing), first trimester termi-
nation placental tissue, purified first trimester cytotrophoblasts
(90% cytokeratin-7-positive), and full term placental fibro-
blasts. Promoter methylation comparable with that seen in full
term placental tissue was observed both in primary and cul-
tured CVS tissue samples (Fig. 2 and Table 1) and in first tri-
TABLE 1
Mean promoter methylation levels of CYP24A1, CYP27B1, and VDR
genes in human placental samples and cell lines
A summary of CpG island methylation status for genes regulating vitamin D
homeostasis and activity was determined by bisulfite sequencing. Placenta, full
term placental tissue; 1st trimester CT, purified cytotrophoblasts showing
95% CK-7 positive staining; Terminated pregnancy, placental tissue at 9–12
weeks gestation; Pre-eclampsia, diseased placental tissue at 9–12 weeks gestation;
Choriocarcinoma, cell lines (BeWo, JEG-3, and/or JAR). Placental fibroblasts were
isolated following serial passaging of Percoll gradient-separated cell fractions.
Decidual cells, human endometrial stromal cells grown in culture. HIPEC65, an
SV40-transformed trophoblast cell line. Normal tissue data consist of pooled data
across a variety of different human tissues isolated from different subjects. The
number of each type of cell/tissue is shown in parentheses.
Gene Tissue Mean methylation S. D.
%
CYP24A1 Placenta (n 8) 56.53 10.49
Uncultured CVS (n 4) 33.07 9.31
Cultured CVS (n 4) 33.79 19.02
First trimester CT (n 4) 48.17 24.49
Terminated pregnancy (n 3) 48.62 19.18
Pre-eclampsia (n 3) 39.85 6.32
Choriocarcinoma (n 3) 80.40 10.47
Placenta fibroblasts (n 3) 2.95 2.28
Decidual cells (n 4) 1.57 0.57
HIPEC65 (n 2) 2.03 0.96
Nonplacental tissue (n 10) 1.56 1.12
CYP27B1 Placenta (n 4) 5.23 4.88
Choriocarcinoma (n 2) 86.63 1.51
VDR Placenta (n 2) 0.65 0.14
Choriocarcinoma (n 3) 85.84 11.61
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mester termination tissue (Table 1). Since the CVS culturing
conditions do not favor trophoblast growth or division, the
methylation of CYP24A1 seen in the cultured samples is prob-
ably mesodermal in origin. In addition, purified first trimester
cytotrophoblasts also show methylation of the CYP24A1 gene
(Fig. 2), demonstrating that this methylation is present in mul-
tiple cell types in first trimester placenta. No methylation was
detected in purified full term placental fibroblasts or an SV40-
transformed first trimester trophoblast cell line (Fig. 2). A sum-
mary of mean methylation levels obtained in this study is pre-
sented in Table 1.
CYP24A1 Methylation Is Placenta-specific—Given the
importance of the 24-hydroxylase enzyme in regulating levels
of active vitaminD, it is surprising how little is known about the
epigenetic regulation of this gene in human tissues. In order to
address this, we assessed the methylation status of the
CYP24A1 gene in a panel of human tissues consisting of kidney,
skeletal muscle, skin fibroblasts, brain (prefrontal cortex),
sperm, whole blood, buccal mucosa, endometrial stroma,
decidualized stroma, bone marrow, and umbilical cord tissue.
The results, (summarized in Fig. 2 and Table 1; detailed in sup-
plemental Fig. 2), demonstrate the specificity of placental
CYP24A1 methylation in humans, with no evidence for meth-
ylation in any human somatic tissue tested.
The CYP24A1Gene Is DifferentiallyMethylated in Full Term
Placentas from Different Mammals—In previous studies, we
have demonstrated that some of the specific promoter methy-
lation recently documented in human term placental tissue is
present in primates but absent in E18 (day 18 of pregnancy)
mouse placenta. We therefore examined methylation of the
CYP24A1 gene promoter regions in full term placenta from
marmoset and mouse E18 and E11.5 (Fig. 3). Assays were
designed to span the region corresponding to the human
CYP24A1-2 assay. This revealed varying levels of CYP24A1
methylation in both marmoset (mean 27 	 18.7%) and mouse
(mean 35.1	 4.5%) placental tissue with generally lower levels
FIGURE 2.Methylation of CYP24A1 in different human placental tissues and cell types. Representative methylation data generated for the CYP24A1-2
assay in cytokeratin-7 positive cytotrophoblasts (A), uncultured CVS (B), cultured CVS (C), full term placental fibroblasts (D), and whole blood (E). i, between 8
and 12 individual clones were sequenced for each sample. Circles, CpG sites denoted by vertical dashes. Closed circles, methylation; open circles, lack of
methylation.Missing circles indicateCpGsites forwhichno informationwasobtained.Grayboxes, toGpG island locations;arrows, start site of translationwithin
exon 1 (black line). ii, mean methylation levels seen at each CpG site for each type of sample tested. Numbers of each type of tissue are listed in parentheses.
Placental Methylation of the Vitamin D 24-Hydroxylase Gene
14842 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 284•NUMBER 22•MAY 29, 2009
relative to that seen in human full term placentas (mean 56.5	
10.5%; Fig. 3) Interestingly, less methylation was seen in E18
mouse placental tissue compared with E11.5 tissue (data not
shown).
Methylation of the Core CYP24A1 Gene Promoter Directly
Attenuates Basal Promoter Activity in Human Trophoblast-de-
rived Cells—Despite circumstantial evidence of an inverse corre-
lation ofCYP24A1mRNA levels with promoter genemethylation
(above), nodirect evidence forDNAmethylation-mediated silenc-
ing of this gene promoter has been reported. To investigate this
further, we PCR-amplified the previously described vitamin
D-responsive region of the human CYP24A1 gene promoter
(47) and generated a luciferase reporter construct to directly
test the effects of promoter methylation on both basal and vita-
min D-induced promoter activity.
The SV40-transformed human trophoblast cell line,
HIPEC65, and choriocarcinoma-derived JAR cells were trans-
fected with two different reporter constructs (plus and minus
orientation) with or without in vitro methylation with SssI or
HpaII methylases. SssI methylase methylates all CpGs; HpaII
methylase methylates only the CpG within the sequence
CCGG. Results, summarized in Fig. 4, reveal a low level of pro-
moter activity of this promoter region in the plus orientation in
both cell lines, 6.5-fold (HIPEC65; p  0.028) and 12-fold
(JAR; p 0.001) higher than that of the promoterless luciferase
vector. Promoter activity in the reverse (minus) orientationwas
negligible (1.3-fold), demonstrating a directionality of the basal
promoter element (data not shown). Basal activity was com-
pletely attenuated by prior methylation with any of SssI (p 
0.011), HpaII (p  0.01), or HhaI (p  0.014) methylases in
HIPEC65 cells and inhibited in the JAR cell line (p 0.001 for
each of SssI and HpaII; supplemental Table 1). The 768-bp
region of this gene used for reporter activity assays contains a
total of 5 HhaI and 15 HpaII methylase target sites, suggesting
that even low level methylation of this promoter is sufficient to
abrogate gene expression activity.
CpG Island Methylation Abrogates 1,25-(OH)2D-mediated
Up-regulation of CYP24A1 Transcription—In addition to
examining the effects of promoter methylation on the basal
CYP24A1 promoter activity, we also set out to investigate the
consequences of this methylation on the previously demon-
strated inducibility of this gene promoter by 1,25-(OH)2D (47).
JAR and HIPEC65 cells were transfected with the 768-bp core
promoter with or without previous methylation with Sss1
methylase as above. 10 h post-transfection, one-half of cells
were supplemented with 100 nM 1,25-(OH)2D, and reporter
(luciferase) activity was then monitored. Although 1,25-
(OH)2D treatment resulted in a clear induction (3.5-fold) of
basal promoter activity in HIPEC65 cells in the absence of pre-
vious promoter methylation (p  0.008), this response was
abolished with in vitro methylation of the reporter construct
prior to transfection (Fig. 4). 1,25-(OH)2D treatment had no
FIGURE 3. Variable levels of CYP24A1 methylation in different mammalian full term placentas. Representative methylation data were generated for
homologous CYP24A1 promoter region in marmoset (A) and mouse (B). i, gray boxes, GpG island locations; arrows, orientation of transcription. Black boxes,
assay location. ii, eight individual clones were sequenced for each sample. Circles, CpG sites denoted by black dashes. Closed circles, methylation; open circles,
lack of methylation. Shaded bars, mean methylation levels seen at each CpG site for each type of sample tested.
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effect on promoter activity in JAR cells (p 0.663), most likely
reflecting the methylation of the VDR gene in this cell line (see
below) that silences the gene and inhibits exogenous 1,25-
(OH)2D signaling through the VDR.
We also examined the effect of promoter methylation on
the induction of endogenous CYP24A1, CYP27B1, and VDR
gene expression in primary cells derived from CVS tissue
(average methylation level of 33.4%) and placental and skin
fibroblasts (both lacking CYP24A1 methylation). Cultured
skin fibroblasts showed a mean CYP24A1 induction level
approaching 2000-fold (n 2; Fig. 5), consistent with previ-
ous data (47, 51, 52). Placental fibroblasts also showed a sig-
nificant level of induction (mean 172-fold; n  2). In con-
trast, cultured CVS cells showed a reduced capacity for gene
induction (mean 10 fold; n  4). In contrast to the major
effects of vitamin D induction on CYP24A1 expression in
skin and placental fibroblasts, VDR expression levels were
slightly reduced (mean reduction of 3-fold) in skin fibro-
blasts, with little change apparent in placental fibroblasts
(mean 1.18-fold increase) and CVS-derived cells (mean 0.76-
fold change; Fig. 5). Similarly, no major effects on CYP27B1
expression level were seen in skin fibroblasts (mean 1.19-fold
increase) or CVS-derived cells (mean 1.55-fold increase) fol-
lowing vitamin D induction (Fig. 5).
Altered CYP24A1 Methylation in
Placental Tissue from Pre-eclamp-
sia Pregnancies?—We carried out a
preliminary analysis of methylation
levels of the CYP24A1-2 assay
region in a small set of available pre-
eclampsia tissue (Table 1). These
samples showed a mean methyla-
tion level of only 39.5	 6% (n 3),
compared with the 56.53 	 10%
level seen in nonpre-eclampsia pla-
cental tissue (n  8). The potential
significance (p  0.017) of these
data will require further investiga-
tion in a larger sample size in the
future.
CompleteMethylation of Vitamin
D Regulatory Genes in Choriocarci-
noma Cell Lines—Trophoblast
hyperplasia is a common feature of
complete and partial hydatidiform
mole with the potential for malig-
nant transformation to choriocarci-
noma (CCA) (53). Trophoblasts
that comprise CCA resemble the
primitive trophoblast of the previl-
lous stage during placental develop-
ment, arrested in specific stages of
differentiation (54).
We analyzed themethylation sta-
tus of CYP24A1 in three widely
studied CCA cell lines, JEG-3,
BeWo, and JAR. In all three lines,
methylation at the CYP24A1 pro-
moter was increased to nearly complete methylation (Fig. 6).
These results correlate with the very low levels of CYP24A1
mRNA seen in each of these cell types (data not shown). We
also assessed methylation at the VDR and CYP27B1 CpG
islands, which also revealed nearly complete methylation of
each of these genes in all cell lines tested. This contrasts with
the complete lack of methylation seen in full term placental
tissue and first trimester cytotrophoblast (described above).
DISCUSSION
Placental insufficiency, due to inadequate remodeling of the
maternal vasculature in early pregnancy, is thought to play a
major role in several adverse pregnancy outcomes, including
the early stages of pre-eclampsia (55). Lowered 1,25-(OH)2D
and altered calcium metabolism have been implicated in this
process (10, 11). For example, a recent Cochrane review of ran-
domized control trials demonstrated a role for calcium supple-
mentation in reducing pre-eclampsia risk.5 Altered expression
levels of 1-hydroxylase,VDR, and 24-hydroxylase genes have all
been reported in different placental cells and tissue from pre-
eclamptic pregnancies, possibly in response to decreasing
5 G. J. Hofmeyr, A. N. Atallah, and L. Duley (2006) Cochrane Database of Sys-
tematic Reviews 3, CD001059, available on the World Wide Web.
FIGURE 4. CYP24A1 promoter activity in human trophoblast cell lines. SV40-transformed cytotrophoblast
(HIPEC-65) or choriocarcinoma (JAR) cells were transfected (n  8 for each cell line) with a promoterless
luciferase reporter (vector) with or without the cloned CYP24A1 gene promoter (548/209 relative to the
start site of transcription). This region has previously been demonstrated to contain vitamin D-responsive
elements (47). Basal promoter activity was detected in both cell lines and was abolished with in vitromethyl-
ation of the promoter prior to transfection (Sss1, HpaII, and HhaI methylases). 1,25-(OH)2D (active vitamin D)
induction of the promoter was observed only in HIPEC-65 cells (JAR cells are predicted to lack the vitamin D
receptor, as evidenced by complete methylation of the associated CpG island), but this induction was attenu-
atedwithpriormethylationof thepromoter region. Luminescence valueswerenormalized toRenilla luciferase
to correct for transfectionefficiency, andall data aredisplayed relative to themeanpromoterless control vector
in HIPEC-65 cells. Error bars denote 95% confidence intervals. Statistical analysis for comparing between trans-
fected groups was carried out using a two-tailed Student’s t test with unequal variance.
Placental Methylation of the Vitamin D 24-Hydroxylase Gene
14844 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 284•NUMBER 22•MAY 29, 2009
maternal 1,25-(OH)2D (19, 57, 58). In addition, levels of
CYP27B1mRNAare reduced in cultured syncytial trophoblasts
derived from pre-eclamptic patients compared with controls
(57). These data highlight the likely functional importance of
1,25-(OH)2D in placental function and implicate disruption of
vitamin D homeostasis in adverse pregnancy outcomes.
Epigenetic regulation of steroid signaling is an emerging field
of research and hints at a complex interplay between environ-
mental or dietary influences with underlying genetic variation,
epigenetic variation, steroid metabolism, and subsequent
downstream effects (59). However, at present, very little is
known about the consequences of altered environmental,
genetic, or epigenetic regulation of vitamin D homeostasis at
the fetomaternal interface. In this study, we found no evidence
for methylation of the VDR or CYP27B1 genes in human full
term or first trimester placental tissue. Since methylation is
generally associated with gene silencing, this supports previous
data demonstrating high levels of expression of 1-hydroxylase
and VDR in the placenta (18, 19, 60). In contrast, we have iden-
tifiedmethylation of theCYP24A1 gene, encoding 24-hydrox-
ylase, the major catabolic enzyme of 1,25-(OH)2D and
25-(OH)2D in placental tissue and cell subtypes.We have dem-
onstrated that this methylation is present in both the tropho-
blast compartment and cells of mesodermal origin and is pres-
ent (albeit at variable levels) in primate and rodent placentas.
This contrasts with the recently described placenta-specific
methylation of theAPC tumor suppressor gene that is primate-
specific and localizes solely to the trophoblast compartment
(37) and the SFRP2 tumor suppres-
sormethylation that is primate-spe-
cific but localizes to multiple pla-
cental cell subtypes (38).
Importantly, we have demon-
strated (by in vitro reporter studies)
that methylation of the CYP24A1
gene promoter directly down-regu-
lates basal gene activity and abol-
ishes vitamin D induction of the
proximal promoter region. This is
further supported by data demon-
strating a reduced inducibility (by
2–3 orders of magnitude) of the
methylated endogenous CYP24A1
gene in cultured primary human
CVS-derived cells relative to
unmethylated fibroblast cells. We
observed much higher levels of
induction of the endogenous gene in
cultured primary fibroblast cells in
comparison with that seen with a
transfected reporter construct (con-
taining only the proximal promoter
region) in transformed trophoblast
cells. This is consistent with previ-
ous data demonstrating a require-
ment for distal upstream sequence
elements, in addition to the two pre-
viously described vitamin D-re-
sponsive elements, contained within the proximal promoter
region, formaximal induction of theCYP24A1 gene (47). Inter-
estingly, we did not find any major effects of exogenous 1,25-
(OH)2D on the levels of VDR or CYP27B1 expression in skin or
placental fibroblast cells. This contrasts with previous studies
showing down-regulation of each of these genes in some cancer
cell lines (61) in response to 1,25-(OH)2D treatment. In addi-
tion, the CYP27B1 gene was recently reported to be down-reg-
ulated in response to 1,25-(OH)2D in cultured trophoblasts
undergoing syncitialization (62). The proximal human
CYP27B1 gene promoter contains putative vitamin D-respon-
sive elements and has been shown to mediate 1,25-(OH)2D-
mediated down-regulation of this gene in in vitro reporter
experiments in mouse proximal tubule cells (63). However, in
primary human keratinocytes, 1,25-(OH)2D does not regulate
1-hydroxylase mRNA or protein expression (64), supporting
our findings in this study.
Methylation of the proximal promoter region of the mouse
Cyp24a1 gene has been previously reported in tumor-derived
endothelial cells, where it contributes to selective growth inhi-
bition by 1,25-(OH)2D (30). Conversely, a lack ofmethylation in
corresponding non-tumor-derived mouse endothelial cells is
associated with a lack of 1,25-(OH)2D-mediated growth inhibi-
tion (30). No equivalent data have previously been reported for
the human CYP24A1 gene.
It is well documented that maternal circulating 1,25-(OH)2D
levels show a dramatic increase during pregnancy (reviewed in
Ref. 12), with 50% of maternal circulating 1,25-(OH)2D
FIGURE 5. Induction of endogenous CYP24A1mRNA in cultured primary cells. Cells were cultured in mul-
tiplewells, and100nM1,25-(OH)2D3 (active vitaminD)wasadded tohalf of the cultures for 7h, followedby total
RNA isolationandquantitative real time reverse transcription-PCR.Mean levels of induction (n2–4) are listed
in the corresponding table. Whereas cultured skin fibroblasts show a nearly 2000-fold induction of CYP24A1
expression, consistent with previous data (47, 51, 52), and placental fibroblasts show a mean 172-fold induc-
tion, cultured CVS biopsies (containing cells with CYP24A1methylation) show a greatly reduced level of gene
induction (10-fold). No major effects on VDR or CYP27B1 expression were observed. Error bars denote 95%
confidence interval. ND, no data available.
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derived from maternal decidua and placenta (13). This obser-
vation demonstrates that the tight regulation of 1,25-(OH)2D
levels is uncoupled during pregnancy. There are two potential
mechanisms by which this can be achieved. First, this can be
achieved through an increase in expression of the CYP27B1
gene, which results in increasing 1-hydroxylase and elevated
production of 1,25-(OH)2D from less active precursors. The
second potential mechanism involves a decrease in the catabo-
lism of 1,25-(OH)2D by the 24-hydroxylase enzyme encoded by
CYP24A1. Increasing levels of maternal circulating 1,25-
(OH)2D during pregnancy have been linked to increased syn-
thesis rather thandecreasing catabolic activity in animal studies
(65–67). In addition, CYP27B1 expression is increased in early
pregnancy decidua in comparison with nonpregnant endome-
trium (19, 68). In this study, we have demonstrated that the
increasing synthesis of 1,25-(OH)2D occurs in concert with a
placenta-specific epigenetic down- regulation of the CYP24A1
(24-hydroxylase) gene. Thus, both mechanisms for elevating
1,25-(OH)2D levels are present during pregnancy.
We are currently investigating the specific role of 1,25-
(OH)2D in mediating various aspects of placental functioning.
1,25-(OH)2D has widely diverse roles in regulating cell division,
apoptosis, and immunemodulation. It also shows antiprolifera-
tive effects in many different cell types, is proapoptotic, and is
inhibitory to cell migration and invasion (5, 6, 69–71). Each of
these processes plays an important role in the development and
function of the mammalian placenta.
The interesting finding of simultaneous methylation of the
VDR, CYP24A1, and CYP27B1 genes in choriocarcinoma-de-
rived trophoblast cell lines is unprecedented in cancer. Methy-
lation of the VDR gene is consistent with recent data demon-
strating a lack of expression in BeWo and JEG-3
choriocarcinoma cell lines (72), and dysregulation of all three
genes has been reported in cancers of different origin (73).
Although abolition of VDR and CYP27B1 expression is antici-
pated to attenuate vitamin D-mediated growth inhibition in
tumor cells, silencing of CYP24A1 would have the effect of
maximizing active vitamin D bioavailability. It is possible that
VDR
A
(i)
(ii)
JEG-3
JAR (2)
(iii)
CYP24A1
Mean (n=3)
B
 (i)
JAR
(ii) JEG-3
(iii) Mean (n=3)
CYP27B1
C
 (i)
(ii)
BEWO
(iii)
JAR
Mean (n=2)
FIGURE 6.Methylation analysis of vitamin D-associated genes in CCA-derived trophoblast cell lines. High levels of methylation were detected for both
VDR (A) and CYP27B1 (C) in choriocarcinoma cell lines (n 2). All choriocarcinoma cell lines (n 3; BeWo not shown) examined showed hypermethylation of
the CYP24A1 gene relative to full termplacental tissue or purified first trimester trophoblasts. Numbers of each type of tissue are listed in parentheses. Between
8 and 12 individual clones were sequenced for each sample. Circles, CpG sites within the assayed region. Closed circles, methylation; open circles, lack of
methylation.Missing circles indicate CpG sites for which no informationwas obtained.Gray boxes correspond toGpG island locations, and arrows denote start
site of translation within exon 1 (black line). iii, mean methylation levels seen at each CpG site for each type of sample tested.
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the precursor cells from which CCA developed already had the
CYP24A1methylation described in this study and that acquisi-
tion of epigenetic silencing of theVDR andCYP27B1 genes was
associated with the development of this tumor type. It is inter-
esting to speculate that a sequential series ofmethylation events
may occur in tumor development andprogression. Future stud-
ies examining the epigenetic regulation of this and other path-
ways in hydatidiform mole, recurring mole, and choriocarci-
noma, may shed valuable light on the acquisition of
methylation changes in gestational tumors.
Confirmation of epigenetic regulation of active vitamin D
levels at the fetomaternal interface provides compelling cir-
cumstantial evidence for the intersection of two metabolic
pathways in regulating pregnancy outcome, namely vitamin D
and 1-carbon (folate or methyl donor) metabolism. One-car-
bonmetabolism is a process by whichmethyl groups are passed
from one donor molecule to the next (74, 75). This cycle pro-
duces S-adenosylmethionine, which donates its methyl group
to cytosine to producemethylatedCpG. Each of these pathways
relies on external inputs for the production of precursor mole-
cules, and enzymes involved in each pathway (including VDR
and CYP27B1) have known functional polymorphic variants
implicated in moderating disease risk (76–83), including
adverse pregnancy outcomes (84–89). There are numerous
polymorphisms throughout theCYP24A1 exonic, intronic, and
regulatory gene regions (56), but as yet there is little informa-
tion regarding the functionality or clinical relevance of such
variants. The convergence/intersection of 1-carbon metabo-
lism with other metabolic and signaling pathways is potentially
very important in modulating disease risk and warrants further
investigation.
The placenta-specific epigenetic regulation of several genes
and metabolic pathways, independent of well characterized
imprinted regions, is now a firmly established phenomenon.
Uncovering the mechanisms leading to the establishment of
such markings, their timing, and sensitivity to environmental
and genetic disruption has the potential to reveal valuable
insights into the evolution of different placental functions and
may reveal novel risk pathways associated with adverse preg-
nancy outcomes and tumor development.
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